Earnings
Financial results, in detail.
Quarterly and annual results for Canopy Growth, with financial statements, MD&A and SEC filings organized by fiscal year. Figures below reflect the fiscal year ended March 31, 2026.
Fiscal year 2026
$284.6M
Total net revenue, FY2026 (+6% YoY)
+15%
Cannabis segment net revenue growth, FY2026
$131.3M
Net cash position at fiscal year-end
-$20.2M
Adjusted EBITDA loss — narrowed 14% YoY
Net revenue by segment
Where the growth came from.
| Segment | Q4 FY26 | Q4 growth | FY26 | FY growth |
|---|---|---|---|---|
| Canada Medical | $25.3M | +27% | $90.8M | +18% |
| Canada Adult-Use | $20.6M | +1% | $94.5M | +20% |
| International Markets Cannabis | $8.6M | +68% | $28.7M | -7% |
| Storz & Bickel (devices) | $16.8M | -14% | $70.7M | -14% |
Consolidated net revenue was $71.2M in Q4 (+10%) and $284.6M for the full year (+6%). Adjusted gross margin held at 28% for fiscal 2026, and free cash flow improved to -$69.1M from -$176.6M a year earlier.
Recent reporting periods
Q4 & Fiscal Year 2026
Reported Jun 15, 2026
Q3 Fiscal 2026
Quarter ended Dec 31, 2025
Q2 Fiscal 2026
Quarter ended Sep 30, 2025
Q1 Fiscal 2026
Quarter ended Jun 30, 2025
Complete financial statements, MD&A and SEC filings (Forms 10-K and 10-Q) for all periods are filed on SEDAR+ and SEC EDGAR.
Outlook